Roxanne C. Jewell

3.1k total citations
59 papers, 1.8k citations indexed

About

Roxanne C. Jewell is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Roxanne C. Jewell has authored 59 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 19 papers in Molecular Biology and 19 papers in Hematology. Recurrent topics in Roxanne C. Jewell's work include Multiple Myeloma Research and Treatments (18 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). Roxanne C. Jewell is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). Roxanne C. Jewell collaborates with scholars based in United States, United Kingdom and Netherlands. Roxanne C. Jewell's co-authors include Elaine Paul, Jan H.M. Schellens, Jos H. Beijnen, W.W. ten Bokkel Huinink, Hilde Rosing, Margaret Schot, C.M.F. Kruijtzer, Ira Gupta, Els O. Witteveen and Sandra A. Radema and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Roxanne C. Jewell

57 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roxanne C. Jewell United States	22	1.1k	608	289	286	270	59	1.8k
Christopher A. Slapak United States	23	1.3k 1.1×	1.1k 1.9×	188 0.7×	252 0.9×	194 0.7×	42	2.3k
Peter Stopfer Germany	28	1.5k 1.3×	878 1.4×	151 0.5×	154 0.5×	184 0.7×	69	2.6k
Paul Noordhuis Netherlands	32	1.7k 1.5×	1.4k 2.3×	257 0.9×	237 0.8×	118 0.4×	82	3.4k
MJ Ratain United States	17	828 0.7×	877 1.4×	227 0.8×	269 0.9×	259 1.0×	34	2.0k
Maja J.A. de Jonge Netherlands	33	1.5k 1.4×	1.7k 2.8×	108 0.4×	219 0.8×	175 0.6×	107	3.1k
N A Brophy United States	10	759 0.7×	429 0.7×	246 0.9×	145 0.5×	143 0.5×	13	1.2k
Jong Gwang Kim South Korea	33	1.5k 1.3×	1.1k 1.8×	65 0.2×	592 2.1×	524 1.9×	203	3.4k
Eugene Mechetner United States	19	1.0k 0.9×	706 1.2×	227 0.8×	68 0.2×	123 0.5×	39	1.8k
Kyung Hwan Kim South Korea	26	994 0.9×	429 0.7×	141 0.5×	145 0.5×	509 1.9×	95	2.2k
Lewis M. Slater United States	21	925 0.8×	647 1.1×	192 0.7×	164 0.6×	178 0.7×	68	1.7k

Countries citing papers authored by Roxanne C. Jewell

Since Specialization

Citations

This map shows the geographic impact of Roxanne C. Jewell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roxanne C. Jewell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roxanne C. Jewell more than expected).

Fields of papers citing papers by Roxanne C. Jewell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roxanne C. Jewell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roxanne C. Jewell. The network helps show where Roxanne C. Jewell may publish in the future.

Co-authorship network of co-authors of Roxanne C. Jewell

This figure shows the co-authorship network connecting the top 25 collaborators of Roxanne C. Jewell. A scholar is included among the top collaborators of Roxanne C. Jewell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roxanne C. Jewell. Roxanne C. Jewell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jewell, Roxanne C., Richard J. Mills, Colm Farrell, & Sandra A. G. Visser. (2024). Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies. British Journal of Clinical Pharmacology. 90(10). 2571–2581. 1 indexed citations

Rathi, Chetan, et al.. (2023). Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1411–1424. 8 indexed citations

Suvannasankha, Attaya, Nizar J. Bahlis, Katja Weisel, et al.. (2022). P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY. HemaSphere. 6. 830–831. 3 indexed citations

Hultcrantz, Malin, David Kleinman, Astrid McKeown, et al.. (2022). Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.. Journal of Clinical Oncology. 40(16_suppl). TPS8073–TPS8073. 6 indexed citations

Suvannasankha, Attaya, Nizar J. Bahlis, Suzanne Trudel, et al.. (2022). Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.. Journal of Clinical Oncology. 40(16_suppl). 8018–8018. 12 indexed citations

Medaglia, Alice Annalisa, Ajay K. Nooka, Nizar J. Bahlis, et al.. (2020). Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm). SHILAP Revista de lepidopterología. 1 indexed citations

Trudel, Suzanne, Ajay K. Nooka, Mala K. Talekar, et al.. (2019). DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). Annals of Oncology. 30. v447–v447. 12 indexed citations

Johnson, Mark, Roxanne C. Jewell, Amanda Peppercorn, et al.. (2018). The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacology Research & Perspectives. 6(4). e00408–e00408. 16 indexed citations

Patton, W. N., Robert W. Lindeman, Andrew C. Butler, et al.. (2015). An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 56(10). 2819–2825. 4 indexed citations

10.

Struemper, Herbert, Mark Sale, Bela Patel, et al.. (2014). Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. The Journal of Clinical Pharmacology. 54(7). 818–827. 22 indexed citations

11.

Matasar, Matthew J., Myron S. Czuczman, Maria Alma Rodriguez, et al.. (2013). Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 122(4). 499–506. 45 indexed citations

12.

Ogura, Michinori, Kiyohiko Hatake, Kensei Tobinai, et al.. (2013). Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Japanese Journal of Clinical Oncology. 43(5). 466–475. 10 indexed citations

13.

Gupta, Ira & Roxanne C. Jewell. (2012). Ofatumumab, the first human anti‐CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Annals of the New York Academy of Sciences. 1263(1). 43–56. 37 indexed citations

14.

Burris, Howard A., Jeffrey R. Infante, Roxanne C. Jewell, et al.. (2010). A Phase I Study of Weekly Topotecan in Combination with Pemetrexed in Patients with Advanced Malignancies. The Oncologist. 15(9). 954–960. 4 indexed citations

15.

Curtis, Kelly K., Roxanne C. Jewell, Peter F. Lebowitz, et al.. (2009). A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m²Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer. The Journal of Clinical Pharmacology. 50(3). 268–275. 7 indexed citations

16.

Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908. 41 indexed citations

17.

Robertson, Michael J., James W. Mier, Theodore F. Logan, et al.. (2006). Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer. Clinical Cancer Research. 12(14). 4265–4273. 126 indexed citations

18.

Sonneveld, Pieter, Ate van der Gaast, Alex Sparreboom, et al.. (2004). A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 55(1). 91–99. 86 indexed citations

19.

Jewell, Roxanne C. & Patrick J. McNamara. (1990). Glutathione Catalysis of lnterconversion of Acitretin and Its 13-cis Isomer lsoacitretin. Journal of Pharmaceutical Sciences. 79(5). 444–446. 9 indexed citations

20.

Jewell, Roxanne C., Kim L. R. Brouwer, & Patrick J. McNamara. (1989). α1-Acid glycoprotein high-performance liquid chromatography column (EnantioPAC) as a screening tool for protein binding. Journal of Chromatography B Biomedical Sciences and Applications. 487(2). 257–264. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact